Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Ribavirin 400 mg vs Copegus in Healthy Adults
NCT05532306Phase 1Completed
- Sponsor
- Future University in Egypt
- Start
- Oct 2020
- Primary completion
- Nov 2020
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ribavirin in hepatitis C (HCV) (2 arms), sponsored by Future University in Egypt. Primary endpoints: Maximum Plasma Concentration at 72 hours and Area Under the Plasma Concentration Curve from Administration to Last Observed at 72 hours. Started Oct 2020; status: completed.
02
Drugs
ribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT05532306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05532306.